Table 1 Characteristics and demographics of the included patients with JIA and the controls
JIA (n = 51) | Controls (n = 50) | ||
|---|---|---|---|
Median (range) or number (%) | |||
Age at enrolment, years | 12.9 (1.6–17.9) | 13.3 (2.0–17.9) | |
Female sex, n | 32 (62.7) | 31 (62) | |
JIA subtype, n | Oligoarticular | 21 (41.2) | N/A |
Polyarticular RF+ | 4 (7.8) | N/A | |
Polyarticular RF- | 13 (25.5) | N/A | |
JPS | 5 (9.8) | N/A | |
Enthesitis-related arthritis | 4 (7.8) | N/A | |
Undifferentiated | 4 (7.8) | N/A | |
Disease duration at inclusion, months | 19 (0 − 161) | ||
Active disease, n | 46 (90.2) | ||
C-reactive protein, mg/L | 9 (5–40) | ||
Erythrocyte sedimentation rate, mm/h | 10 (2–34) | ||
ANA+, n | 22 (43.1) | ||
RF+, n | 5 (9.8) | ||
Anti-CCP+, n | 6 (11.8) | ||
RF+/anti-CCP+, n | 4 (7.8) | ||
NSAID, n | 28 (54.9) | ||
Oral steroids, n | 16 (31.3) | ||
Intraarticular steroids, n | 32 (62.7) | ||
Conventional synthetic DMARDs, n | 27 (52.9) | ||
Methotrexate | 23 (45.1) | ||
Sulfasalazine | 4 (7.8) | ||
Biological DMARDs, n | 8 (15.7) | ||
Adalimumab | 4 (7.8) | ||
Etanercept | 4 (7.8) | ||